Please assess the completion status of the following clinical trial:

Trial Title: MLE4901 vs. Placebo for the Treatment of PCOS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Oligo-/amenorrhea~2. At least one of the following during Screening:~   * Clinical signs of hyperandrogenism, where clinical hyperandrogenism may include hirsutism (defined as excessive terminal hair that appears in a male pattern), acne, or androgenic alopecia~  * Biochemical hyperandrogenism refers to an elevated serum androgen level (i.e., total, bioavailable or free testosterone level ≥ULN)~  * Polycystic ovarian morphology, defined as the presence of 12 or more follicles 2-9 mm in diameter and/or an increased ovarian volume \>10 mL (without a cyst or dominant follicle) in either ovary~3. Body mass index (BMI) 22 to 45 kg/m2, inclusive~4. Must be willing to avoid use of all hair removal procedures and products during study participation~5. Must be willing to avoid all prescription treatments for acne and not increase the dose or frequency of their current non-prescription acne treatment regimen during study participation~6. Must be willing to avoid the use of all hair growth procedures and products during study participation~7. Permanently surgically sterilized (bilateral salpingectomy or tubal occlusion) \>2 years or male partner(s) has had a vasectomy \>2 years or must consent to use two permitted medically-acceptable methods of contraception throughout the study during any sexual intercourse with a male partner. Permitted medically-acceptable methods of birth control for this study are defined as use of a male condom plus one of the following: spermicide, diaphragm with spermicide, or an intrauterine device that does not contain steroid hormones.~Exclusion Criteria:~1. Menopausal or peri-menopausal, defined for this study as FSH (follicle stimulating hormone ) \>10 IU/L~2. Irregular vaginal/menstrual bleeding caused by conditions other than PCOS (e.g., uterine polyps or submucosal uterine fibroids)~3. Abnormal Papanicolaou (Pap) test during Screening requiring follow-up sooner than 1 year after the test~4. Uncontrolled hypo- or hyperthyroidism~5. Post-hysterectomy or endometrial ablation~6. Post-oophorectomy (unilateral or bilateral) or other ovarian surgery~7. Medical history of type 1 or type 2 diabetes mellitus

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Plain, round, biconvex, white film-coated tablets that appear identical to MLE4901 tablets
- MLE4901 (Type: EXPERIMENTAL): Plain, round, biconvex, white film-coated tablets administered twice per day

Based on this trial design, predict the completion outcome and termination type (if applicable).